Trial Profile
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy (DUAL III -GLP-1 Switch)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Exenatide; Liraglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL-III
- Sponsors Novo Nordisk
- 16 Jun 2020 Results from indirect treatment comparisons between two randomized controlled trials, presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 05 Oct 2018 Results of a post-hoc analysis from DUAL I-V and VII studies, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes